Please login to the form below

Not currently logged in


This page shows the latest DPP-4 news and features for those working in and with pharma, biotech and healthcare.

Novo’s diabetes pill defeats Merck’s Januvia in trial

Novo’s diabetes pill defeats Merck’s Januvia in trial

Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... PIONEER 4 saw the enrolment of 711 people with type 2 diabetes

Latest news

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Merck and Pfizer are hoping that Steglujan will benefit from piggy-backing on Merck’s Januvia - the top-selling DPP-4 inhibitor - backed by some strong clinical data for the combination ... which as yet is the only fixed-dose SGLT2/DPP-4 inhibitor

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.

  • FDA won't add outcomes data to Januvia label FDA won't add outcomes data to Januvia label

    The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying ... It also found no

  • Boehringer Ingelheim calls for Boehringer Ingelheim calls for "strong and united" Europe

    The pharma unit benefited from a tighter focus on prescription drugs, with sales last year rising 7.4% to 12bn. ... In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The approval of Qtern is good news for patients who may benefit from

More from news
Approximately 5 fully matching, plus 74 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    This acquisition brings a phase I oral DPP 4, evogliptin, and an immunomodulator, cenicriviroc (CVC), for treating non-alcoholic steatohepatitis (NASH). ... OncoImmune / Pfizer. Option agreement. Exclusive option to ONC-392 a preclinical CTLA-4 candidate.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    Boehringer's interest in the area is a relatively recent one and is focused on its major partnership with Lilly, which so far has produced Trajenta – a DPP-4 inhibitor for

  • Pharma deals during April 2013 Pharma deals during April 2013

    standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....